No profile data available.
Beam Therapeutics Inc. (BEAM) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Cambridge, United States, with about 540 full-time employees.
It reported revenue of $63.52 million for fiscal year 2024, down 83.2% from fiscal year 2023, and net income of -$376.74 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $9.70 million, down 32.0% from a year before. Its market capitalization was $2.65 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.
Beam Therapeutics reported $63.52 million in revenue for fiscal year 2024, down 83.2% from $377.71 million in fiscal year 2023. In Q3 2025 revenue was $9.70 million.
$2.65 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Organon & Co. (OGN), Viking Therapeutics, Inc. (VKTX), Prestige Consumer Healthcare Inc. (PBH), Terns Pharmaceuticals, Inc. (TERN).